Conference Reports for NATAP

ICAAC 48th Annual ICAAC / IDSA 46th Annual Meeting October 25-28, 2008 Washington, DC Back

A Phase II Safety and Efficacy Study of Bevirimat in Heavily Treatment-Experienced HIV+ Patients Identifies the Target Phase III Study Profile       Reported by Jules Levin ICAAC/IDSA Oct 28 2008 Wash DC   Jacob Lalezari, Scott McCallister, Maria Gigliotti, Calvin Cohen, Richard Elion, Cynthia Brinson, Gary Richmond, Melanie Thompson, David Martin   AUTHOR CONCLUSIONS   Short-term safety data are comparable between placebo and bevirimat-treated patients   All patients receiving bevirimat liquid doses of at least 250mg QD had trough levels > 20 ug/mL   Patients free of baseline Gag polymorphisms at codons 369, 370 or 371 are most likely to respond to bevirimat treatment   Phase III Target Profile Patients had a mean viral load reduction of -1.11 log10 copies/mL